Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biohaven (BHVN) Common Equity (2021 - 2026)

Biohaven has reported Common Equity over the past 6 years, most recently at $129.5 million for Q1 2026.

  • Quarterly results put Common Equity at $129.5 million for Q1 2026, down 50.1% from a year ago — trailing twelve months through Mar 2026 was $129.5 million (down 50.1% YoY), and the annual figure for FY2025 was $52.1 million, up 103.87%.
  • Common Equity reached $129.5 million in Q1 2026 per BHVN's latest filing, up from $52.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $538.8 million in Q4 2022 and bottomed at -$1.3 billion in Q4 2024.
  • Median Common Equity over the past 5 years was $282000.0 (2023), compared with a mean of -$27.2 million.
  • The largest annual shift saw Common Equity soared 1453.06% in 2022 before it plummeted 409013.25% in 2024.
  • Over 5 years, Common Equity stood at $538.8 million in 2022, then dropped by 20.56% to $428.0 million in 2023, then crashed by 414.44% to -$1.3 billion in 2024, then surged by 103.87% to $52.1 million in 2025, then soared by 148.69% to $129.5 million in 2026.
  • Business Quant data shows Common Equity for BHVN at $129.5 million in Q1 2026, $52.1 million in Q4 2025, and -$17.2 million in Q3 2025.